Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Gathering Around Cancer 2020 | Osimertinib for EGFR-mutant lung cancer

Jarushka Naidoo • 4 Nov 2020
Gathering Around Cancer 2020
Lung Cancer Non-Small Cell Lung Cancer Osimertinib
FLAURA

Jarushka Naidoo, MBBCh, Beaumont Hospital, Dublin, Ireland, outlines the approval and reimbursement of osimertinib in patients with EGFR mutant non-small cell lung cancer, based on the results of the FLAURA study. (NCT02296125). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology)

More from Jarushka Naidoo

1:11
Unanswered questions regarding the use of IO in NSCLC
Jarushka Naidoo • 5 Jun 2022
1:28
Highlights in NSCLC from ASCO 2022
Jarushka Naidoo • 5 Jun 2022
0:48
Chemotherapy-free immunotherapy-based treatment approaches for NSCLC
Jarushka Naidoo • 5 Jun 2022
1:44
Post-hoc subgroup analysis from PACIFIC: durvalumab after CRT in unresectable stage III EGFRm NSCLC
Jarushka Naidoo • 5 Jun 2022

Related Videos

2:45
Assessing operability in NSCLC: challenges and considerations
Mariana Brandao • 18 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals